PAVMED INC.

One Grand Central Place, Suite 4600

New York, New York 10165

 

October 4, 2017

 

Securities and Exchange Commission

Division of Corporation Finance

Washington, DC 20549

 

  Re: PAVmed Inc.
    Registration Statement on Form S-3
    Filed September 21, 2017
    File No. 333-220549

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, PAVmed Inc. (the “Company”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement (File No. 333-220549), so that such Registration Statement will become effective at 4:30 p.m. Eastern Time on Friday, October 6, 2017, or as soon thereafter as practicable.

 

In connection with the Company’s request for acceleration of the effectiveness of the above-referenced Registration Statement, the Company acknowledges the following:

 

  should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
     
  the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
     
  the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

  Sincerely,
   
  PAVMED INC.
   
  By: /s/ Lishan Aklog, M.D.
  Name: Lishan Aklog, M.D.
  Title: Chairman and Chief Executive Officer